{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,11,5]],"date-time":"2025-11-05T20:39:09Z","timestamp":1762375149146,"version":"3.40.4"},"reference-count":22,"publisher":"S. Karger AG","issue":"6","license":[{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"},{"start":{"date-parts":[[2006,1,1]],"date-time":"2006-01-01T00:00:00Z","timestamp":1136073600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.karger.com\/Services\/SiteLicenses"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Oncology"],"published-print":{"date-parts":[[2006]]},"abstract":"<i>Background:<\/i> Various chemotherapeutic agents as well as the anti-CD20 antibody rituximab (R) have been tested in patients with mucosa-associated lymphoid tissue (MALT) lymphoma, but no standard chemotherapeutic regimen has emerged so far. Judging from the data obtained in various types of lymphoma, the activity of R appears to be enhanced by combination with chemotherapy. As no data on this topic exist for MALT lymphoma, we have retrospectively analysed our experience with R plus cyclophosphamide, doxorubicin\/mitoxantrone, vincristine and prednisone (R-CHOP\/R-CNOP) in patients with relapsed MALT lymphoma. <i>Patients and Methods:<\/i> A total of 26 patients were identified, 15 were administered R-CHOP while 11 patients were given R-CNOP due to age >65 years or pre-existing cardiac conditions. Cycles were repeated every 21 days, and restaging was performed after 4 cycles of therapy. In case of complete remission, 2 further cycles were administered for consolidation while patients achieving partial remission or stable disease after restaging were given 4 further courses. <i>Results:<\/i> A total of 170 cycles were administered to our patients (median 6, range 2\u20138). Twenty of the 26 patients (77%) achieved a complete remission and 6 (23%) a partial remission. Toxicities were mainly haematological, with WHO grade III\/IV leukocytopenia occurring in 5 patients. After a median follow-up of 19 months (range 10\u201345), all patients are alive: 22 are in ongoing remission, while 4 have relapsed between 12 and 19 months after treatment. <i>Conclusions:<\/i> Our data demonstrate a high activity of R-CHOP\/R-CNOP in relapsing MALT lymphoma irrespective of prior therapy.<\/jats:p>","DOI":"10.1159\/000098555","type":"journal-article","created":{"date-parts":[[2007,1,12]],"date-time":"2007-01-12T12:21:57Z","timestamp":1168604517000},"page":"411-417","source":"Crossref","is-referenced-by-count":49,"title":["Activity of Rituximab plus Cyclophosphamide, Doxorubicin\/Mitoxantrone, Vincristine and Prednisone in Patients with Relapsed MALT Lymphoma"],"prefix":"10.1159","volume":"70","author":[{"given":"Markus","family":"Raderer","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Stefan","family":"W\u00f6hrer","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Berthold","family":"Streubel","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Johannes","family":"Drach","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ulrich","family":"J\u00e4ger","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Karl","family":"Turetschek","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Marlene","family":"Troch","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"P\u00fcsp\u00f6k","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Christoph C.","family":"Zielinski","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andreas","family":"Chott","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"127","published-online":{"date-parts":[[2007,2,23]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.1016%2FS1085-5629%2800%2980013-9"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.1023%2FA%3A1008396618983"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.02.3903"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1136%2Fgut.53.1.34"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdi277"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.1158%2F1078-0432.CCR-04-2282"},{"key":"ref7","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2006.06.0723"},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.05.660"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2002.05.117"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.1159%2F000079502"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2004.00.8532"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.1002%2Fcncr.20237"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.1093%2Fannonc%2Fmdg492"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.1159%2F000074641"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2002-11-3496"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1200%2FJCO.2005.08.128"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1056%2FNEJMoa011795"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2005-01-0016"},{"key":"ref19","doi-asserted-by":"publisher","DOI":"10.1182%2Fblood-2004-08-3175"},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1136%2Fgut.52.11.1656"},{"key":"ref21","doi-asserted-by":"publisher","DOI":"10.1158%2F1078-0432.CCR-04-0803"},{"key":"ref22","doi-asserted-by":"publisher","DOI":"10.1080%2F10428190500178399"}],"container-title":["Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/98555","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.karger.com\/Article\/Pdf\/98555","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,24]],"date-time":"2025-04-24T02:32:30Z","timestamp":1745461950000},"score":1,"resource":{"primary":{"URL":"https:\/\/karger.com\/article\/doi\/10.1159\/000098555"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2006]]},"references-count":22,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2007,2,1]]}},"URL":"https:\/\/doi.org\/10.1159\/000098555","archive":["Portico"],"relation":{},"ISSN":["0030-2414","1423-0232"],"issn-type":[{"type":"print","value":"0030-2414"},{"type":"electronic","value":"1423-0232"}],"subject":[],"published":{"date-parts":[[2006]]}}}